August 10, 2010 07:00 AM Eastern Daylight Time
BUSINESS WIRE

Phase 3 ILLUMINATE Study Supports 24-Week Telaprevir-Based Therapy Within a Response-Guided Regimen for People with Hepatitis C Who Had Not Received Prior Treatment

Download